Express News | Eli Lilly Shares up 1.3% Premarket After Co's Weight-Loss Drug Tops Rival Wegovy in Head-to-Head Study

Reuters1minutes ago

Express News | Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

Benzinga2minutes ago

Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%

PR Newswire3minutes ago

Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study -- WSJ

WSJ3minutes ago

Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial

Reuters3minutes ago

Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%

Reuters3minutes ago